title: [Effect of pharmacologic blockade of the autonomic nervous system on electrophysiologic properties of the accessory pathway and atrioventricular node in patients with Wolff-Parkinson-White syndrome].
abstract: In 17 patients aged 21-61 (mean 32) with WPW syndrome the transoseophageal stimulation was performed before and after intravenous administration of propranolol (0.1 mg/kg b.w.) and atropine (0.02 mg/kg b.w.). Pharmacological blockade of the autonomic nervous system resulted in statistically significant increase of heart rate (from 81 to 111/min), shortening of a-v nodal and atrial refraction (from 298 to 272 ms) as well as in shortening of stimuli cycle length revealing Wenckebach's point (from 324 to 291 ms). The Kent bundle refraction did not at the average change (333 and 324 ms), while in individuals great differences were observed. Generally, pharmacological blockade of the autonomic nervous system improves a-v nodal conduction, but in patients with WPW syndrome does not significantly effect on the accessory pathway.
authors.forename: W
authors.initials: W
authors.lastname: Molenda
authors.forename: C
authors.initials: C
authors.lastname: Telichowski
authors.forename: W
authors.initials: W
authors.lastname: Banasiak
authors.forename: J
authors.initials: J
authors.lastname: Góral
authors.forename: J
authors.initials: J
authors.lastname: Petruk
authors.forename: J
authors.initials: J
authors.lastname: Zebrowski
mesh_terms: D000328:Adult; D001283:Atrioventricular Node / Q000187:drug effects / Q000503:physiopathology; D001340:Autonomic Nerve Block; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology*; D014927:Wolff-Parkinson-White Syndrome / Q000503:physiopathology*
chemical_list: D011433:Propranolol
vernacular_title: Wpływ blokady farmakologicznej wegetatywnego układu nerwowego na właściwości elektrofizjologiczne drogi dodatkowej i wezła przedsionkowo-komorowego u chorych z zespołem Wolffa-Parkinsona-White'a.